Eloxx Pharmaceuticals Inc. has announced a delay in its financial reporting, as disclosed in a Notification of Late Filing (Form NT 10-Q) with the SEC. The company was unable to file its Annual Reports on Form 10-K for the fiscal years ending December 31, 2024, and 2023 due to financial constraints that prevented engaging an independent public accounting firm for audits. The delay affects the reporting period ended March 31, 2025, as stated in the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.